Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up

CompletedOBSERVATIONAL

Enrollment

414

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 12, 2022

Study Completion Date

December 12, 2022

Conditions

Neovascular Age-related Macular Degeneration

Trial Locations (1)

Novartis, East Hanover